Trial Profile

Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CV 8102 (Primary) ; Programmed cell death 1 receptor antagonists
Indications Adenoid cystic carcinoma; Head and neck cancer; Malignant melanoma; Skin cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors CureVac

03 Nov 2021 Status changed from recruiting to active, no longer recruiting.
21 Sep 2021 Preliminary results from the completed dose escalation part presented at the 46th European Society for Medical Oncology Congress
16 Aug 2021 According to a CureVac media release, the company expects to updates on the progress of this study at the European Society for Medical Oncology (ESMO) congress and the Society for Immunotherapy of Cancer (SITC) annual meeting later this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com